(J Am Heart Assoc. 2020;9:e014330 DOI: 10.1161/JAHA.119.014330.)32441184

For Sources of Funding and Disclosures, see page 12.

OHCA

:   out‐of‐hospital cardiac arrest

ROSC

:   return of spontaneous circulation

RR

:   risk ratio

RCTs

:   randomized controlled trials

Clinical PerspectiveWhat Is New?This meta‐analysis evaluated the efficacy of early application of adrenaline and compared the outcomes between patients with initial shockable and non‐shockable rhythms.Our data show that early pre‐hospital administration of adrenaline to out‐of‐hospital cardiac arrest patients might increase the rate of survival to discharge, return of spontaneous circulation and favorable neurologic outcomes.Cardiac arrest patients with an initial shockable rhythm had a significantly higher rate of survival to discharge and more favorable neurological outcome than cardiac arrest patients with a non‐shockable rhythm.What Are the Clinical Implications?Our finding highlights that early use of adrenaline may be useful for out‐of‐hospital cardiac arrest patients.When evaluating the effects of adrenaline, patients should be stratified by initial cardiac arrest rhythm; otherwise, this difference may influence the outcomes.

 {#jah35134-sec-0009}

Out‐of‐hospital cardiac arrest (OHCA) remains a major public health problem in developed countries.[1](#jah35134-bib-0001){ref-type="ref"}, [2](#jah35134-bib-0002){ref-type="ref"} Approximately 40 000 cases in Canada and 420 000 cases in the United States occur annually.[3](#jah35134-bib-0003){ref-type="ref"}, [4](#jah35134-bib-0004){ref-type="ref"} Based on 81 864 cases in CARES (Cardiac Arrest Registry to Enhance Survival) 2018, the rate of survival to hospital discharge after OHCA treated by emergency medical services was 10.4%, with only 8.2% surviving with good functional status.[5](#jah35134-bib-0005){ref-type="ref"} The routine administration of adrenaline upon cardiac arrest has been recommended since 1974.[6](#jah35134-bib-0006){ref-type="ref"} The current American Heart Association and European Resuscitation Council guidelines for adult cardiac arrest state that 1 mg of adrenaline should be given every 3 to 5 minutes during resuscitation.[7](#jah35134-bib-0007){ref-type="ref"}

The rationale for the use of adrenaline is that adrenaline was shown to increase aortic blood pressure and coronary perfusion pressure during chest compressions in animals,[8](#jah35134-bib-0008){ref-type="ref"}, [9](#jah35134-bib-0009){ref-type="ref"} and this result was also confirmed in humans.[10](#jah35134-bib-0010){ref-type="ref"} However, in recent years, the use of adrenaline has been brought into question because it may be associated with poor neurological outcomes, overall rates of return of spontaneous circulation (ROSCs) and survival to discharge.[11](#jah35134-bib-0011){ref-type="ref"}, [12](#jah35134-bib-0012){ref-type="ref"}, [13](#jah35134-bib-0013){ref-type="ref"}, [14](#jah35134-bib-0014){ref-type="ref"}

Three systematic reviews have been conducted,[15](#jah35134-bib-0015){ref-type="ref"}, [16](#jah35134-bib-0016){ref-type="ref"}, [17](#jah35134-bib-0017){ref-type="ref"} and the results did not support adrenaline administration in OHCA patients. However, the association between outcomes and the time of adrenaline administration was unknown. The timing of adrenaline administration plays a key role in cardiac arrest resuscitation strategies. Observational studies have previously reported that the potential benefits of adrenaline may be limited for early‐phase administration.[18](#jah35134-bib-0018){ref-type="ref"}, [19](#jah35134-bib-0019){ref-type="ref"}, [20](#jah35134-bib-0020){ref-type="ref"}, [21](#jah35134-bib-0021){ref-type="ref"}, [22](#jah35134-bib-0022){ref-type="ref"}, [23](#jah35134-bib-0023){ref-type="ref"} It is believed that emphasis should be placed on the "time‐dependent" effectiveness of adrenaline administration.[24](#jah35134-bib-0024){ref-type="ref"} Therefore, we conducted a systematic review and meta‐analysis, aiming to determine the efficacy of early (time to adrenaline ≤10 minutes) pre‐hospital adrenaline administration in OHCA patients.

Methods {#jah35134-sec-0010}
=======

The authors declare that all supporting data, analytic methods, and study materials within the article and the online supporting information are available to other researchers. This systematic review was performed in adherence with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines.[25](#jah35134-bib-0025){ref-type="ref"} The PRISMA checklist is provided in Table [S1](#jah35134-sup-0001){ref-type="supplementary-material"}. The study was registered with PROSPERO (International Prospective Register of Systematic Reviews; CRD42019130542). Institutional Review Board approval was not required for this systematic review and meta‐analysis.

Search Strategy and Study Eligibility {#jah35134-sec-0011}
-------------------------------------

A systematic search of the scientific literature was performed. The search was conducted from inception to February 2019 in PubMed, EMBASE, Google Scholar, and the Cochrane Library database. The terms used for the search were as follows: ("heart arrest" OR "out‐of‐hospital cardiac arrest" OR "ventricular fibrillation" OR "pulseless electrical activity" OR "PEA" OR "asystole" OR "cardiac arrest") AND ("epinephrine" OR "adrenaline").

Studies were selected by 2 independent reviewers if they met the following inclusion criteria: (1) patients with OHCA were enrolled; (2) the patients were treated with epinephrine; (3) when multiple studies from the same institute were available, to avoid overlapping information, only the study with the largest sample size was included for each analysis; (4) randomized controlled trials (RCTs) or observational studies; and (5) the study outcomes were stated. Inter‐reviewer agreement was determined using Cohen kappa coefficients.

Data Extraction {#jah35134-sec-0012}
---------------

Data were extracted by 2 independent reviewers (L.Y.R., J.L.L.). Any disagreement was discussed with the senior author (W.H.). Study and participant characteristics were extracted. In addition, clinical data including initial cardiac rhythms, dose of adrenaline administered, presumed cardiac origin, witnessed cardiac arrest and bystander cardiopulmonary resuscitation status were also extracted.

Outcomes {#jah35134-sec-0013}
--------

The primary outcome was survival to discharge. The secondary outcomes were ROSC, favorable neurological outcome at hospital discharge/1 month according to a cerebral performance category of 1 or 2,[26](#jah35134-bib-0026){ref-type="ref"}, [27](#jah35134-bib-0027){ref-type="ref"} and survival to hospital admission.

Risk of Bias Assessment {#jah35134-sec-0014}
-----------------------

The Newcastle‐Ottawa scale, which assesses the quality of non‐randomized studies,[28](#jah35134-bib-0028){ref-type="ref"} was used to assess the risk of bias according to 3 aspects: selection, comparability, and outcome. Higher numbers of stars indicate better quality; the study quality was characterized as low (0--4 stars), moderate (5--6 stars), or high (7--9 stars). *The Cochrane Handbook of Systematic Reviews* for intervention tool[29](#jah35134-bib-0029){ref-type="ref"} was used to assess the risk of bias in each RCT. This tool evaluates the biases of 7 items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. We assessed the risk of bias for each domain as low, unclear, or high risk of bias.

Statistical Analysis {#jah35134-sec-0015}
--------------------

The efficacy was estimated for each study by the risk ratio (RR) along with its 95% CI. *P*\<0.05 were considered significant. Heterogeneity was assessed based on the I^2^ test (I^2^\>50, implying substantial heterogeneity). Across the studies, if no significant heterogeneity (defined as I^2^\<50%) was found, the results were combined with the fixed‐effects model (Mantel--Haenszel)[30](#jah35134-bib-0030){ref-type="ref"}; otherwise, the random‐effects model (DerSimonian‐Laird)[31](#jah35134-bib-0031){ref-type="ref"} was used. A sensitivity analysis was performed by serially excluding each study to determine its influence. STATA version 12.0 (StataCorp, College Station, TX) was used to evaluate the outcomes. Finally, the quality of evidence was assessed in accordance with the Grading of Recommendations Assessment, Development and Evaluation approach,[32](#jah35134-bib-0032){ref-type="ref"} to provide reliable evidence for clinical selection.

Subgroup Analysis {#jah35134-sec-0016}
-----------------

A subgroup analysis was performed, and the patients administered adrenaline were stratified by shockable rhythm (ventricular fibrillation and pulseless ventricular tachycardia) and non‐shockable rhythm (pulseless electrical activity and asystole).

Results {#jah35134-sec-0017}
=======

Study Selection {#jah35134-sec-0018}
---------------

Of the 3393 studies retrieved by the literature search, 349 duplicates were removed, leaving 3044 studies available for screening. After screening the title and abstract, 160 studies underwent full‐text review. Of these studies, 9 randomized clinical trials and 15 observational studies were included. The search strategy is shown in Figure [1](#jah35134-fig-0001){ref-type="fig"}. The inter‐reviewer agreement for the 5 inclusion criteria during the second review phase ranged from "good" to "very good" (κ: 0.768--1.000; Table [S2](#jah35134-sup-0001){ref-type="supplementary-material"}).

![Flow diagram of the study selection.\
 ](JAH3-9-e014330-g001){#jah35134-fig-0001}

Study Characteristics {#jah35134-sec-0019}
---------------------

The basic characteristics of the studies are summarized in [Table](#jah35134-tbl-0001){ref-type="table"}. A total of 574 392 participants were included. Twenty‐two studies included patients with shockable and non‐shockable rhythms, and only 2 studies included patients with non‐shockable rhythms.[23](#jah35134-bib-0023){ref-type="ref"}, [33](#jah35134-bib-0033){ref-type="ref"} Eighteen studies only enrolled patients administered adrenaline; and 4 studies compared adrenaline to vasopressin. Eight studies reported outcomes where the time to adrenaline administration was within 10 minutes[18](#jah35134-bib-0018){ref-type="ref"}, [19](#jah35134-bib-0019){ref-type="ref"}, [21](#jah35134-bib-0021){ref-type="ref"}, [23](#jah35134-bib-0023){ref-type="ref"}, [34](#jah35134-bib-0034){ref-type="ref"}, [35](#jah35134-bib-0035){ref-type="ref"}, [36](#jah35134-bib-0036){ref-type="ref"}, [37](#jah35134-bib-0037){ref-type="ref"}; 19 studies compared the outcomes between shockable and non‐shockable rhythm patients.[11](#jah35134-bib-0011){ref-type="ref"}, [12](#jah35134-bib-0012){ref-type="ref"}, [18](#jah35134-bib-0018){ref-type="ref"}, [33](#jah35134-bib-0033){ref-type="ref"}, [34](#jah35134-bib-0034){ref-type="ref"}, [36](#jah35134-bib-0036){ref-type="ref"}, [38](#jah35134-bib-0038){ref-type="ref"}, [39](#jah35134-bib-0039){ref-type="ref"}, [40](#jah35134-bib-0040){ref-type="ref"}, [41](#jah35134-bib-0041){ref-type="ref"}, [42](#jah35134-bib-0042){ref-type="ref"}, [43](#jah35134-bib-0043){ref-type="ref"}, [44](#jah35134-bib-0044){ref-type="ref"}, [45](#jah35134-bib-0045){ref-type="ref"}, [46](#jah35134-bib-0046){ref-type="ref"}, [47](#jah35134-bib-0047){ref-type="ref"}, [48](#jah35134-bib-0048){ref-type="ref"}, [49](#jah35134-bib-0049){ref-type="ref"}, [50](#jah35134-bib-0050){ref-type="ref"} Four studies were based on data from the All‐Japan Utstein Registry.[21](#jah35134-bib-0021){ref-type="ref"}, [35](#jah35134-bib-0035){ref-type="ref"}, [37](#jah35134-bib-0037){ref-type="ref"}, [40](#jah35134-bib-0040){ref-type="ref"}

###### 

Characteristics of Included Studies

  Study                                                             Country                         Study Period   Design       Sample    Age, y      Initial Cardiac Rhythm n (%)   Cardiac cause (%)   Witnessed Arrest (%)   Bystander CPR (%)   Intervention   Comparator                                         
  ----------------------------------------------------------------- ------------------------------- -------------- ------------ --------- ----------- ------------------------------ ------------------- ---------------------- ------------------- -------------- -------------------------------------------------- ------------------------------------------------------
  Callaham et al, 1992[38](#jah35134-bib-0038){ref-type="ref"}      United States                   1990--1992     RCT, MC      816       65±18.6     24.4                           75.6                NA                     52.3                16.4           Adrenaline                                         No adrenaline
  Cantrell et al, 2013[34](#jah35134-bib-0034){ref-type="ref"}      United States                   2009           Cohort, MC   660       63.1±16.8   24.2                           75.8                NA                     53                  46             Administration of adrenaline \<10 min              Administration of adrenaline \>10 min
  Dumas et al, 2014[12](#jah35134-bib-0012){ref-type="ref"}         France                          2000--2012     Cohort, SC   1556      59.8±16     54.3                           45.7                NA                     84.6                43.8           Adrenaline                                         No adrenaline
  Ewy et al, 2015[33](#jah35134-bib-0033){ref-type="ref"}           United States                   2005--2013     Cohort, MC   3469      66.3±15.1   41.8                           58.2                100                    100                 49.4           Administration of adrenaline in shockable rhythm   Administration of adrenaline in non‐shockable rhythm
  Fisk et al, 2018[39](#jah35134-bib-0039){ref-type="ref"}          United States                   2008--2016     Cohort, SC   2255      63.7±17.7   24.6                           75.4                NA                     36.6                52.7           Administration of adrenaline in shockable rhythm   Administration of adrenaline in non‐shockable rhythm
  Funada et al, 2018[35](#jah35134-bib-0035){ref-type="ref"}        Japan                           2011--2014     Cohort, SC   124 856   77±14.8     0                              100                 52.5                   100                 48.5           Adrenaline                                         No adrenaline
  Gotoet al, 2013[40](#jah35134-bib-0040){ref-type="ref"}           Japan                           2009--2010     Cohort, MC   209 577   74±16.1     7.4                            92.6                56.7                   35.7                45.7           Adrenaline                                         No adrenaline
  Gueugniaud et al, 1998[41](#jah35134-bib-0041){ref-type="ref"}    France and Belgium              1994--1996     RCT, MC      3327      65.6±15     17                             83                  71.6                   78.8                9.8            Standard doses of adrenaline                       High doses of adrenaline
  Gueugniaud, 2008[42](#jah35134-bib-0042){ref-type="ref"}          France                          2004--2006     RCT, MC      2894      61.5±15     9.2                            90.8                35.9                   75.2                26.8           Adrenaline                                         Adrenaline+vasopressin
  Guyette et al, 2004[43](#jah35134-bib-0043){ref-type="ref"}       United States                   2002--2003     Cohort, SC   298       63.8±15.1   26.8                           68.8                NA                     44                  28.2           Adrenaline                                         No adrenaline
  Hansen et al, 2018[52](#jah35134-bib-0052){ref-type="ref"}        United States, Canada           2011--2015     Cohort, MC   32 101    68+19.5     0                              100                 8.5                    40.2                40.9           Administration of adrenaline \<10 min              Administration of adrenaline \>10 min
  Hayashi et al, 2012[18](#jah35134-bib-0018){ref-type="ref"}       Japan                           2007--2009     Cohort, MC   3161      73.3+15.2   16                             84                  67.3                   100                 41.6           Adrenaline                                         No adrenaline
  Holmberg et al, 2002[44](#jah35134-bib-0044){ref-type="ref"}      Sweden                          1990--1995     Cohort, MC   10 966    67.3        56.7                           43.3                NA                     66.8                32.2           Adrenaline                                         No adrenaline
  Hubble and Tyson, 2017[36](#jah35134-bib-0036){ref-type="ref"}    United States                   2012--2014     Cohort, MC   1917      66.3±14.8   31                             69                  NA                     100                 52             Administration of adrenaline \<10 min              Administration of adrenaline \>10 min
  Jacobs et al, 2011[45](#jah35134-bib-0045){ref-type="ref"}        Australia                       2006--2009     RCT, SC      534       64.6±17.4   49                             51                  91.4                   55.8                51.1           Adrenaline                                         Placebo
  Bar‐Joseph et al, 2005[46](#jah35134-bib-0046){ref-type="ref"}    Israel                          1990--1992     RCT, MC      2122      65.7        49.4                           49                  NA                     NA                  42             Adrenaline and low sodium bicarbonate              Adrenaline and high sodium bicarbonate
  Koscik et al, 2013[19](#jah35134-bib-0019){ref-type="ref"}        United States                   2005--2011     Cohort, MC   686       69±17       25                             75                  NA                     47                  NA             Administration of Adrenaline \<10 min              Administration of Adrenaline \>10 min
  Mukoyama et al, 2009[47](#jah35134-bib-0047){ref-type="ref"}      Japan                           2001--2006     RCT, SC      336       65.4±17     24                             76                  100                    44.3                15.1           Adrenalin                                          Vasopressin
  Nakahara et al, 2012[37](#jah35134-bib-0037){ref-type="ref"}      Japan                           2007--2008     Cohort, MC   49 165    76±15       16.4                           83.6                67.5                   100                 45.7           Adrenaline                                         No adrenaline
  Olasveengen et al, 2012[11](#jah35134-bib-0011){ref-type="ref"}   Norway                          2003--2008     RCT, SC      848       66±18       33.5                           66.5                71                     65.3                100            Adrenaline                                         No adrenaline
  Ong et al, 2007[48](#jah35134-bib-0048){ref-type="ref"}           Singapore                       2002--2004     Cohort, MC   1296      64±16       20.3                           79.7                NA                     67.3                19.4           Adrenaline                                         No adrenaline
  Ong et al, 2012[49](#jah35134-bib-0049){ref-type="ref"}           Singapore                       2006--2009     RCT, MC      727       65±15       7.7                            88.2                86.2                   72.9                15.4           Adrenaline                                         Vasopressin
  Tanaka et al, 2016[21](#jah35134-bib-0021){ref-type="ref"}        Japan                           2006 --2012    Cohort, MC   119 639   71±14       23.7                           76.3                100                    100                 45             Adrenaline                                         No adrenaline
  Wenzel et al, 2004[50](#jah35134-bib-0050){ref-type="ref"}        Austria, Germany, Switzerland   1999 --2002    RCT, MC      1186      66±14       39.8                           60.2                60.6                   77.6                18.4           Adrenaline                                         Vasopressin

CPR indicates cardiopulmonary resuscitation; MC, multiple centers; NA, not applicable; Non‐shockable, pulseless electrical activity and asystole; RCT, randomized controlled trial; SC, single center; and Shockable, ventricular fibrillation and pulseless ventricular tachycardia.

Risk of Bias Assessment {#jah35134-sec-0020}
-----------------------

Fifteen adult cohorts were assessed for risk of bias using the Newcastle‐Ottawa scale (Table [S3](#jah35134-sup-0001){ref-type="supplementary-material"}). All studies were categorized as high quality. The potential sources of bias in RCTs are summarized in Figure [S1](#jah35134-sup-0001){ref-type="supplementary-material"} and displayed in Figure [S2](#jah35134-sup-0001){ref-type="supplementary-material"}. Two RCTs were assessed as "low risk of bias", 7 RCTs were assessed as having "unclear risk of bias" for at least 1 domain, and no study was assessed having a "high risk of bias".

Adrenaline Administration Within 10 Minutes Versus Adrenaline Administration After 10 Minutes {#jah35134-sec-0021}
---------------------------------------------------------------------------------------------

The results of 4 studies[19](#jah35134-bib-0019){ref-type="ref"}, [23](#jah35134-bib-0023){ref-type="ref"}, [36](#jah35134-bib-0036){ref-type="ref"}, [37](#jah35134-bib-0037){ref-type="ref"} were pooled to examine the effects of early adrenaline administration on survival to discharge, with a sample size of 28 700 in the shockable rhythm group and 5989 in the non‐shockable rhythm group (Figure [2](#jah35134-fig-0002){ref-type="fig"}). A fixed‐effects model was used; the pooled RR in the shockable rhythm group was 1.68 (95% CI, 1.48--1.90; *P*\<0.001, I^2^=65.0%); in the non‐shockable rhythm group, the pooled RR was 1.36 (95% CI, 1.00--1.85; *P*=0.053, I^2^=0.0%), indicating that a patient with shockable rhythm cardiac arrest receiving pre‐hospital adrenaline within 10 minutes was 1.68 times more likely to survive to discharge than one receiving pre‐hospital adrenaline after 10 minutes. The quality of the evidence was assessed as low (Figure [S3](#jah35134-sup-0001){ref-type="supplementary-material"}).

![Effects of early (\<10 minutes vs \>10 minutes) pre‐hospital adrenaline administration on survival to discharge/1 month.\
RR indicates risk ratio.](JAH3-9-e014330-g002){#jah35134-fig-0002}

Data from 4 studies[19](#jah35134-bib-0019){ref-type="ref"}, [21](#jah35134-bib-0021){ref-type="ref"}, [34](#jah35134-bib-0034){ref-type="ref"}, [36](#jah35134-bib-0036){ref-type="ref"} were pooled for the analysis of pre‐hospital ROSC, with a total of 6403 patients with shockable rhythm cardiac arrest and 17 179 patients with non‐shockable rhythm cardiac arrest (Figure [3](#jah35134-fig-0003){ref-type="fig"}). A fixed‐effects model was used, and the pooled RR in the shockable rhythm group was 1.58 (95% CI, 1.38--1.81; *P*\<0.001, I^2^=80.8%); a sensitivity analysis was performed because of the significant heterogeneity when excluding the study[21](#jah35134-bib-0021){ref-type="ref"} that included only cardiac arrest patients. The heterogeneity decreased to 42.9%, with a pooled RR of 1.35 (95% CI, 1.15--1.60; *P*\<0.001). In the non‐shockable rhythm group, the pooled RR was 1.44 (95% CI, 1.23--1.68; *P*\<0.001, I^2^=0.0%), indicating a greater likelihood of experiencing pre‐hospital ROSC in patients administered pre‐hospital adrenaline within 10 minutes. The quality of the evidence was assessed as low (Figure [S3](#jah35134-sup-0001){ref-type="supplementary-material"}).

![Forest plot for pooling the effects of early (\<10 minutes vs \>10 minutes) pre‐hospital adrenaline administration on return of spontaneous circulation.\
ROSC indicates return of spontaneous circulation; and RR, risk ratio.](JAH3-9-e014330-g003){#jah35134-fig-0003}

We included 5 studies[18](#jah35134-bib-0018){ref-type="ref"}, [21](#jah35134-bib-0021){ref-type="ref"}, [35](#jah35134-bib-0035){ref-type="ref"}, [36](#jah35134-bib-0036){ref-type="ref"}, [37](#jah35134-bib-0037){ref-type="ref"} in a pooled analysis of favorable neurological outcomes (cerebral performance category 1--2), with a total of 6302 patients with shockable rhythm cardiac arrest and 33 454 patients with non‐shockable rhythm cardiac arrest (Figure [4](#jah35134-fig-0004){ref-type="fig"}). A fixed‐effects model was used; the pooled RR in the shockable rhythm group was 3.21 (95% CI, 2.54--4.05, *P*=0.000; I^2^=55.2%), and the pooled RR in the non‐shockable rhythm group was 1.58 (95% CI, 1.20--2.09; *P*=0.001, I^2^=0.0%). This result suggested that a patient with shockable rhythm cardiac arrest receiving pre‐hospital adrenaline within 10 minutes was 3.21 times more likely to experience a favorable neurological outcome than one receiving pre‐hospital adrenaline after 10 minutes. The quality of the evidence was assessed as moderate (Figure [S3](#jah35134-sup-0001){ref-type="supplementary-material"}). One study[12](#jah35134-bib-0012){ref-type="ref"} did not report initial cardiac rhythm separately; when the study was included, the pooled overall RR was 2.03 (95% CI, 1.73--2.39; *P*\<0.001, I^2^=81.2%) (Figure [S4](#jah35134-sup-0001){ref-type="supplementary-material"}).

![Forest plot for pooling the effects of early (\<10 minutes vs \>10 minutes) pre‐hospital adrenaline administration on achieving a cerebral performance category of 1 to 2.\
CPC indicates cerebral performance category; and RR, risk ratio.](JAH3-9-e014330-g004){#jah35134-fig-0004}

Shockable Rhythm Versus Non‐Shockable Rhythm {#jah35134-sec-0022}
--------------------------------------------

Fourteen studies were included to observe the pooled effect of adrenaline administration on survival to discharge, with a sample size of 21 844 patients with shockable rhythm cardiac arrest and 208 284 patients with non‐shockable rhythm cardiac arrest (Figure [5](#jah35134-fig-0005){ref-type="fig"}A). A random‐effects model was used; the pooled RR was 5.86 (95% CI, 4.25--8.07; *P*\<0.001, I^2^=89.6%), which indicated that a patient with shockable rhythm cardiac arrest was 5.86 times more likely to survive to discharge than one with non‐shockable rhythm cardiac arrest. The quality of the evidence was assessed as high (Figure [S5](#jah35134-sup-0001){ref-type="supplementary-material"}).

![**A**, Forest plot comparing survival to discharge between patients who had shockable and non‐shockable rhythm cardiac arrest; **B**, Forest plot comparing return of spontaneous circulation between patients who had shockable and non‐shockable rhythm cardiac arrest.\
ROSC indicates return of spontaneous circulation; and RR, risk ratio.](JAH3-9-e014330-g005){#jah35134-fig-0005}

Fourteen studies were included to observe the pooled effects of adrenaline administration on pre‐hospital ROSC, with a sample size of 19 480 patients with shockable rhythm cardiac arrest and 205 671 patients with non‐shockable rhythm cardiac arrest (Figure [5](#jah35134-fig-0005){ref-type="fig"}B). A random‐effects model was used; the pooled RR was 1.51 (95% CI, 0.91--2.50; *P*=0.11, I^2^=99.5%), and there was no significant difference between the groups. The quality of the evidence was assessed as high (Figure [S5](#jah35134-sup-0001){ref-type="supplementary-material"}).

Eight studies were included to observe the pooled effects of adrenaline administration on favorable neurological outcome (cerebral performance category 1--2), with a sample size of 7317 patients with shockable rhythm cardiac arrest and 27 411 patients with non‐shockable rhythm cardiac arrest (Figure [6](#jah35134-fig-0006){ref-type="fig"}A). A random‐effects model was used; the pooled RR was 5.10 (95% CI, 2.90--8.97; *P*\<0.001, I^2^=94.1%), indicating that a patient with shockable rhythm cardiac arrest was 5.10 times more likely to experience a favorable neurological outcome than one with non‐shockable rhythm cardiac arrest. The quality of the evidence was assessed as high (Figure [S5](#jah35134-sup-0001){ref-type="supplementary-material"}).

![**A**, Forest plot comparing the effects of a cerebral performance category of 1 to 2 between patients who had shockable and non‐shockable rhythm cardiac arrest;\
**B**, Forest plot comparing survival to admission between patients who had shockable and non‐shockable rhythm cardiac arrest. RR indicates risk ratio.](JAH3-9-e014330-g006){#jah35134-fig-0006}

Ten studies were included to observe the pooled effects of adrenaline administration on survival to admission, with a sample size of 2359 patients with shockable rhythm cardiac arrest and 9655 patients with non‐shockable rhythm cardiac arrest (Figure [6](#jah35134-fig-0006){ref-type="fig"}B). A random‐effects model was used; the pooled RR was 1.45 (95% CI, 1.33--1.58; *P*\<0.001, I^2^=17.6%), suggesting a higher rate of survival to admission in patients with shockable rhythm cardiac arrest than in patients with non‐shockable rhythm cardiac arrest. The quality of the evidence was assessed as high (Figure [S5](#jah35134-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah35134-sec-0023}
==========

In this systematic review and meta‐analysis, we evaluated the effects of early pre‐hospital administration of adrenaline in OHCA patients. Our results indicated that the administration of adrenaline within 10 minutes significantly increased the survival to discharge, ROSC, and favorable neurological outcomes. In addition, compared with non‐shockable cardiac arrest patients, shockable cardiac arrest patients seemed to have a significantly improved prognosis, especially in terms of survival to discharge and favorable neurological outcome.

The use of adrenaline has been reported to result in severe neurological impairment. In a recent randomized, double‐blind trial,[14](#jah35134-bib-0014){ref-type="ref"} Perkins et al found that severe neurologic impairment was more frequent in the adrenaline group than in the placebo group (31.0% versus 17.8%). Although a more favorable neurologic outcome at discharge was observed in the adrenaline group than in the placebo group, the difference was not significant (2.2% versus 1.9%). In addition, these authors also reported a significantly higher rate of 30‐day survival in the adrenaline group than in the placebo group. In another double‐blind randomized controlled trial, Jacobs et al[45](#jah35134-bib-0045){ref-type="ref"} reported that although pre‐hospital ROSC was significantly improved, the outcomes, including survival to discharge and favorable neurological survival, did not differ.

In contrast, in recent years, several studies have reported that a potential benefit of adrenaline was only seen with early administration.[18](#jah35134-bib-0018){ref-type="ref"}, [19](#jah35134-bib-0019){ref-type="ref"}, [20](#jah35134-bib-0020){ref-type="ref"}, [22](#jah35134-bib-0022){ref-type="ref"}, [51](#jah35134-bib-0051){ref-type="ref"}, [52](#jah35134-bib-0052){ref-type="ref"} In a multicenter observational study,[19](#jah35134-bib-0019){ref-type="ref"} Hayashi et al reported that among shockable rhythm cardiac arrest patients, 66.7% of the patients who received adrenaline within 10 minutes had neurologically intact 1‐month survival; however, the rate decreased to 24.9% in patients without adrenaline administration. Fukuda et al[22](#jah35134-bib-0022){ref-type="ref"} performed a similar propensity score‐matched study of 237 068 patients; compared with the patients who did not receive adrenaline administration, the patients who received adrenaline within 15 minutes had a significantly higher rate of survival to 1 month and favorable neurological survival, regardless of whether the patients had shockable or non‐shockable rhythm cardiac arrest. Our results are consistent with the results of these previous studies. In the present study, our findings supported the effects of early adrenaline administration on increasing survival to discharge, overall ROSC, and favorable neurological outcome.

The American Heart Association guidelines[53](#jah35134-bib-0053){ref-type="ref"} recommend that for cardiac arrest with a shockable rhythm, it may be reasonable to administer epinephrine after initial defibrillation attempts have failed. In our subgroup analysis stratified by initial cardiac arrest rhythm, early administration of adrenaline improved the outcomes in both shockable and non‐shockable rhythm cardiac arrest patients. The patients with shockable rhythm cardiac arrest were found to have significantly higher rates of survival to discharge, favorable neurological outcomes and survival to admission than patients with non‐shockable rhythm cardiac arrest in the adrenaline administration group. The different outcomes between the shockable and non‐shockable rhythm groups might be because of the fact that defibrillation plays an important role in the prognosis of patients with shockable rhythm cardiac arrest; this difference indicates that when evaluating the effects of adrenaline, the initial cardiac rhythm should be considered a key factor for predicting the outcomes, and the patients should be stratified by initial cardiac arrest rhythm. Otherwise, this difference may influence the outcomes.

There were several potential limitations in this meta‐analysis. First, our primary and secondary outcomes were based on a maximum of 3 to 4 studies, and only a few of the studies reported the effects of early adrenaline administration. Consequently, more studies are needed to confirm this conclusion. Second, most of the studies that were included were observational studies, making it difficult to adjust for confounders such as the number of doses provided, witnessed arrest, bystander cardiopulmonary resuscitation, emergency medical service response time, and the use of cointerventions. Third, interventions performed in the hospital, such as targeted temperature management and percutaneous coronary intervention, could not be measured or accounted for. Finally, because of insufficient data, we could not perform a comparison with a no adrenaline group; further studies are needed for this comparison. Despite these limitations, the present study included a large sample size from 13 countries, which may help to increase the reliability of the results.

Conclusions {#jah35134-sec-0024}
===========

This systematic review and meta‐analysis suggested that early pre‐hospital administration of adrenaline in OHCA patients might increase the rate of survival to discharge, ROSC, and favorable neurologic outcomes. However, large randomized, controlled studies are needed to further confirm the results.
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